Rius Medical

The next generation of biological drugs: Commercial cell therapies are expected to revolutionise healthcare and address growing clinical needs of an aging population and associated age-related degenerative disorders. If not sure, look at Novartis and Gilead-Kite that brought in genetically engineered T-cells (CAR T-cells). Both market approved cell therapies that target leukemia, an aggressive haematological/blood disorder mainly affecting people of older age.

Rius Medical is in a unique position to offer promising new therapeutics to patients that otherwise have extremely limited options for recovery. Rius Medical is founded on world-class science out of leading Japan and Canada research institutes. Rius Medical approach is based on the pioneering work from Prof. Mitsuo Oshimura published in 2011 that makes production of cells capable to express multiple genes of interest for a variety of applications in biomedicine and biotechnology, including gene therapy and cell therapies. Also the pioneering work from Dr. Keith Humphries on Normal Hematopoietic Stem Cells – the genes and processes controlling key properties of self-renewal and Acute Myeloid Leukemia – the genes and processes underlying transformation of normal blood cells to leukaemic growth. Importantly, these pioneering works combine (i.e. Rius Medical), stand out to re-invent engineered cell therapies for varied patient applications.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

Rius Medical benefits from the support of Prof. Mitsuo Oshimura (Molecular Genetics and Biofunction, Faculty of Medicine at Tottori University), developer of human artificial chromosome for use as gene delivery vectors that overcome problems in existing viral and non-viral systems; thus bringing chromosomes engineering technology on a “shared laboratory format” open to private companies. This greatly reduce the Series A financing round to EUR 1,4 million for TWO programs!

Are you an investor focused on the development of the most promising biotechnology start-ups in Europe? Seeking to invest in highly innovative research business opportunities, such as Rius Medical addressing large unmet medical needs.

PS: October Update, lead investor or second investor position is available.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de 

I am wondering how the investment option offered by my company can best be relayed to investors. Application Service Provider (ASP) is the best analogy I can think of. How to install and manage software on users' computers!

Similar to SaaS, where IT software licenses and deployment models provide functionality to target users, my company applies genetic programming to stem cells. Genetic programming of cells is the 2012 Nobel Prize in Physiology or Medicine www. The market application is numerous, therefore many products under the one platform technology that my company develops.

No installation is required as cell therapy is immediately available to patients. My company is a license and distribution model based, with which cell therapy applications are offered i.e. as a service.

Bottom Line for EUR 25,000 investment: An investment of EUR 25,000 as Convertible Loan at a discounted rate of 0.50 euro per share implies EUR 2,700,000 financial benefits on FIVE products, if not EUR 525,000 financial benefits on TWO products at year 2 (i.e. December 2021). Alternatively there is the option of EUR 25,000 Classical LOAN (1 year maturity, yet full repayment at the latest mid-September 2020) with 30% interest p.a. for EUR 32,500 repayment.

Bottom Line for EUR 400,000 investment: EUR 400,000 against 8% ownership in Rius Medical, an EXIT opportunity at year 2 (i.e. December 2021) for the second investor shall result in EUR 21,6 million financial benefit for FIVE products, if not EUR 4,2 million financial benefit for TWO products.

Investors seeking technologies to improve lives and generate returns, are welcome to inquirer on Rius Medical’s cutting-edge technology that also enlist Artificial Intelligence to address the current and future Coronavirus outbreaks, i.e. COVID-19 pandemic!.

Many thanks and warmest regards,

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de 

Rius Medical – Innovative Science and Technology are at the Heart of Everything we do!

For the few investors seeking life sciences venture in early-stage companies, this announcement bring fourth innovative new ideas where Artificial Intelligence combine with innovative biotech technologies speed up development process of therapeutics to address the current and future Coronavirus outbreaks.

[Reuters, July 2020] Six months into a global COVID-19 pandemic that has infected more than 12 million people, questions remain about whether the antibody response to this virus is robust and lasts over time www. As scientists question whether the presence, or absence, of antibodies to the novel Coronavirus can reliably determine immunity, some are looking to a different component of the immune system, known as T cells, for their role in protecting people in the pandemic.

[Blog, July 2020] Dr. Francis Collins, Director of the United States National Institutes of Health (NIH) commented the following: Much of the study on the immune response to SARS-CoV-2, the novel Coronavirus that causes COVID-19, has focused on the production of antibodies. But, in fact, immune cells known as memory T cells also play an important role in the ability of our immune systems to protect us against many viral infections, including – it now appears – COVID-19 www. What’s clear from this study “by Bertoletti’s team” is our past experiences with Coronavirus infections may have something important to tell us about COVID-19.

Artificial Intelligence comes to the rescue in taming the Coronavirus literature www. AI and biomedical Developers are a great union. The COVID-19 literature has grown in much the same way as the disease’s transmission: exponentially. Artificial Intelligence refers to a broader idea where machines can execute tasks "smartly".  Artificial Intelligence (AI) applies machine learning, deep learning and other techniques to solve actual problems. Deep learning is an artificial intelligence function that imitates the workings of the human brain in processing data and creating patterns for use in decision-making. The goal is to provide an even more powerful environment for mining COVID-19 literature that lists more than 28,000 articles — far too many for any researcher/scientist to read.

Investors seeking technologies to improve lives and generate returns, here with Rius Medical, are welcome to inquirer on Rius Medical’s cutting-edge technology that also enlist Artificial Intelligence to improve lives and generate returns! Your investment in Rius Medical “Scale up” manufacturing processes for multiple products also enables the development of therapeutics to address the current and future Coronavirus outbreaks.

Are you against a brief 3 minutes talk to learn more?

Many thanks and warmest regards,

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de

Rius Medical has made it its mission to further support the cell and gene therapy industry by channelling its expertise into developing technologies that enables “scale up” manufacturing processes.

Rius Medical develops proprietary cell lines for drug delivery. What we do are novel protein therapeutics and a drug delivery technology combine. The Rius Medical project is available to all investors, as published on EuroQuity ¹ and on European Investment Project Portal (EIPP) ². On Angel Invest Network (UK) www Rius Medical is seeking from business angels up to EUR 50,000 Convertible Loan at a discounted rate of 0.50 euro per share.

Lead Investor, Resource Link Consulting Group transferred EUR 1,000,000 financing and pending EUR 24,000 surety bond payment, this project is implemented as of September 2020. An additional EUR 400,000 investment is pending the second investor Sanabil Investments, a sovereign wealth fund of Saudi Arabia completing Due Diligence. Otherwise 8% ownership at EUR 400,000 is available to other investors.

Addressing Coronavirus is with NK cells manufacturing and providing Blood for transfusion! January 2020, Sorrento and Celularity initiated Emergency Allogeneic Natural Killer Cell Therapy Development for Coronavirus Infection www. It is the view of Rius Medical that addressing the 2019 Coronavirus outbreak must exploit NK cells as a therapeutic agent. Rius Medical believes that off-the-shelf natural killer (NK) cells therapy is to be the primary weapon in addressing the 2019 Coronavirus outbreak. The attached documents highlights why that is the case.

Regardless of the form, are we on the right track with Coronavirus vaccine? March 17, 2020, the European Commission offered up to EUR 80 million in financial support to the German biotech CureVac AG (RNA-based vaccine) after it was reported that US President Donald Trump attempted to secure exclusive access to a COVID-19 vaccine CureVac is developing www. As a secondary weapon, it is Rius Medical view that vaccine development must be performed. However, the documents in attachment highlight my support for an alternative as primary weapon. That’s because vaccines utilising mRNA platforms remain an unproven technology, with no vaccine approved for use to date www.

Bottom Line for EUR 25,000 investment: An investment of EUR 25,000 as Convertible Loan at a discounted rate of 0.50 euro per share implies EUR 2,700,000 financial benefits on FIVE products, if not EUR 525,000 financial benefits on TWO products at year 2 (i.e. December 2021). Alternatively there is the option of EUR 25,000 Classical LOAN (1 year maturity, yet full repayment at the latest mid-September 2020) with 30% interest p.a. for EUR 32,500 repayment. More information is available in the attachments.

Are you against a brief 3 minutes talk to learn more?

Many thanks and warmest regards,

Denis Demarais

Founder and CEO

Email: denisdemarais@riusmedical.de